Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site.
about
Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA.Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibitionCrystal structure of norwalk virus polymerase reveals the carboxyl terminus in the active site cleftHIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitroShould we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testingStructures of complexes formed by HIV-1 reverse transcriptase at a termination site of DNA synthesis.Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.Computational Analysis of Molecular Interaction Networks Underlying Change of HIV-1 Resistance to Selected Reverse Transcriptase Inhibitors.Nucleotide-dependent conformational change governs specificity and analog discrimination by HIV reverse transcriptase.A Ty1 reverse transcriptase active-site aspartate mutation blocks transposition but not polymerizationGenotypic testing for human immunodeficiency virus type 1 drug resistance.Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug designConformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.High-throughput virtual screening of phloroglucinol derivatives against HIV-reverse transcriptase.Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapyThe K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutationsInvolvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitorsMutations proximal to the minor groove-binding track of human immunodeficiency virus type 1 reverse transcriptase differentially affect utilization of RNA versus DNA as template.Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimensThe evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.Computational investigation of locked nucleic acid (LNA) nucleotides in the active sites of DNA polymerases by molecular docking simulationsMolecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Polymerase-catalyzed synthesis of DNA from phosphoramidate conjugates of deoxynucleotides and amino acids.Compartmentalization of the gut viral reservoir in HIV-1 infected patients.Fluorescent HIV-1 Dimerization Initiation Site: design, properties, and use for ligand discoveryFormation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.Aptamers that recognize drug-resistant HIV-1 reverse transcriptaseNonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNAThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Intracellular nucleotide levels and the control of retroviral infections.Mechanism of HIV antiretroviral drugs progress toward drug resistance.Redesigning the leaving group in nucleic acid polymerization.Mode of inhibition of HIV-1 reverse transcriptase by polyacetylenetriol, a novel inhibitor of RNA- and DNA-directed DNA polymerases.The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.Iminodiacetic-phosphoramidates as metabolic prototypes for diversifying nucleic acid polymerization in vivo.
P2860
Q27640046-957F5227-FA86-4AFE-B2F5-DDD52B58C04AQ27640261-B936D454-2C66-4835-816F-0E9F44C7D696Q27643088-2CFCF0EB-F9EF-4F62-B799-C5E15B9C9366Q27676835-703D7934-A9AA-4807-949B-B3CE3FC9C466Q28362567-53E76DFC-52EA-4EC2-80A8-5C3619EC7455Q28471687-4C88ADCB-492A-44FC-B712-4B8357C5FA32Q30654060-82DE18F7-73C9-4A87-8237-F7B0BB239120Q33649797-DB1FA7BD-034D-4888-A024-214B39CE9E34Q33793189-33924276-8B42-4A16-871F-BC59AB23D55CQ33842807-E55C8FF7-98F1-4190-9C3A-2143AC767940Q33842826-4027C890-774F-4D74-A85A-67D34B8F53CEQ33906239-11CCF819-206B-4E00-A0AF-9B3DA2CFC432Q34053804-72E3F337-A279-41D9-A1A7-5810E8CE9EECQ34163065-9D04228F-F53B-4179-A1CE-626670432053Q34556651-C7C8AADC-3503-4549-853E-026506248F23Q34577134-157BDEC3-6C29-42CD-88F3-1AFE7ED9721AQ34647936-991A5F33-628B-487B-9C6D-5492AC5D4A35Q34717615-D09A30BC-33E1-4CEC-8D73-89AB85B249DFQ34976998-AB60BF44-E0D7-466A-ADEB-DF1205E5362BQ35004847-3281FDAC-81AD-4C10-ACE3-173F3EF10ED1Q35042225-AB586DE5-3E8C-405C-B38B-C2C7A711517BQ35208705-740D2B19-3D1E-44FD-AA5D-DBAC25DA112AQ35566910-254A780A-8EB3-46DF-A2B2-310D891AE115Q35633587-6B191FCE-EB00-45CE-AE19-21D379C922ACQ35742512-CFEEC002-BD3C-440C-8BA4-311B52ADB34FQ35990894-E38E0C39-1CDA-478B-9C80-B8C61FF5E704Q36412750-B76D5F5A-7FF9-466E-AEB2-65F9B51B5D35Q36852633-D4D018A8-4633-4A6E-8B1B-3858F5C66EE7Q36928993-9E595BED-F50C-4957-AE75-4AF5BDDE95E0Q36986716-077E646C-20B1-40BF-A3B0-3F4566121B1BQ37011076-5376E971-D104-44C4-A253-6599D6DC0DA7Q37018369-87F24C15-A801-4F4F-BE9E-3224E166941BQ37244704-407EF4B4-81E5-498F-9C54-7659215BEFF2Q37961181-3EA28709-6447-495D-A439-7141DBA5B19CQ38019714-27156D47-731E-4ED4-A3D6-83A405B9FBDEQ38291464-63F42769-B2D1-4A7F-B885-FF33FCE89192Q39590457-A3B4757C-35CA-4827-B844-76625756D915Q39657878-123BC13B-83D2-4A84-A331-2148475BA5A6Q39796529-24B43B10-01F9-48B8-9A01-D0251244890FQ40209793-140508EC-1763-47EC-8D0A-B5079742DCAE
P2860
Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Touching the heart of HIV-1 dr ...... at the polymerase active site.
@ast
Touching the heart of HIV-1 dr ...... at the polymerase active site.
@en
type
label
Touching the heart of HIV-1 dr ...... at the polymerase active site.
@ast
Touching the heart of HIV-1 dr ...... at the polymerase active site.
@en
prefLabel
Touching the heart of HIV-1 dr ...... at the polymerase active site.
@ast
Touching the heart of HIV-1 dr ...... at the polymerase active site.
@en
P2093
P1476
Touching the heart of HIV-1 dr ...... at the polymerase active site.
@en
P2093
P304
P356
10.1016/S1074-5521(99)80071-4
P577
1999-05-01T00:00:00Z